×
Jeśli w ciągu kilku sekund nie nastąpi przekierowanie, kliknij
tutaj
.
Wszystko
Grafika
Wiadomości
Wideo
Mapy
Zakupy
Książki
Narzędzia wyszukiwania
Szukaj w internecie
Szukaj w internecie
Tylko język polski
Najnowsze
Najnowsze
Ostatnia godzina
Ostatnie 24 godziny
Ostatni tydzień
Ostatni miesiąc
Ostatni rok
Archiwa
Według trafności
Według trafności
Według daty
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) in Vascular Ehlers-Danlos Syndrome
The Ehlers Danlos Society
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) in Vascular Ehlers-Danlos Syndrome. The pharmaceutical company, Acer...
31 miesięcy temu
Zevra adds Edsivo for vEDS to its rare disease portfolio in new...
Ehlers-Danlos News
Zevra Therapeutics is adding Edsivo (celiprolol), an experimental therapy for vascular Ehlers-Danlos syndrome (vEDS), to its clinical...
8 miesięcy temu
Consensus statement from The Ehlers-Danlos Society and professional members of the vEDS community
The Ehlers Danlos Society
Celiprolol and vEDS: facts, limitations and recommendations. In the context of the recent press about celiprolol and the FDA announcement...
57 miesięcy temu
Acer Therapeutics Axes 60% of Workforce after FDA Rebuff
Genetic Engineering and Biotechnology News
Acer Therapeutics has eliminated about 60% of its workforce—29 jobs—and halted pre-commercialization activities for its lead candidate...
59 miesięcy temu
Edsivo Gets Breakthrough Therapy Status for Vascular Ehlers-Danlos Syndrome
Medical Professionals Reference
The FDA has granted Breakthrough Therapy designation to Edsivo (celiprolol) for the treatment of patients with COL3A1-positive vEDS.
26 miesięcy temu
FDA Rejects Acer Therapeutics' Rare Disease Drug, Calls for New Trial
BioSpace
The Complete Response Letter indicated the company will need to run an “adequate and well-controlled trial to determine whether celiprolol...
59 miesięcy temu
FDA kicks back Acer's rare disease drug, demands new test—shares in freefall
Fierce Biotech
Acer Therapeutics' stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo...
59 miesięcy temu
Celiprolol May Be Protective in COL3A1-positive Vascular EDS Patients
Ehlers-Danlos News
Celiprolol is used to treat hypertension (high blood pressure), and it is thought to benefit vEDS patients by reducing blood pressure in vessels...
40 miesięcy temu
FDA Rejects Edsivo NDA for Vascular Ehlers-Danlos Syndrome
Medical Professionals Reference
The FDA stated that the Company will need to conduct an adequate and well-controlled trial to evaluate the efficacy of Edsivo in patients...
59 miesięcy temu
Edsivo Named FDA Breakthrough Therapy for COL3A1-positive vEDS
Ehlers-Danlos News
Edsivo (celiprolol) has been named a breakthrough therapy by the FDA for COL3A1-positive vascular Ehlers-Danlos syndrome.
26 miesięcy temu